Clinical Trial Update: A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma [NA]

View source ↗

Summary

A pilot study evaluating a ketogenic diet in combination with nivolumab and ipilimumab for metastatic renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Renal Cell Carcinoma | NA | Status: TERMINATED